Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

2 terminated out of 32 trials

Success Rate

88.2%

+1.7% vs benchmark

Late-Stage Pipeline

13%

4 trials in Phase 3/4

Results Transparency

13%

2 of 15 completed with results

Key Signals

2 with results88% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (7)
P 1 (2)
P 2 (4)
P 3 (2)
P 4 (2)

Trial Status

Completed15
Not Yet Recruiting8
Unknown7
Terminated2

Trial Success Rate

88.2%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT07265336Not ApplicableCompleted

Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant Women

NCT07703826Not Yet Recruiting

Identification of Genes of Interest for Severe Forms of Preeclampsia

NCT07665112Not ApplicableNot Yet RecruitingPrimary

Algorithm-Based Timing of Delivery Using the sFlt-1/PlGF Ratio in Early-Onset Severe Preeclampsia. (MAP 2 Study : Management Based on Angiogenic Markers in Preeclampsia 2 Study )

NCT07648251Phase 2Not Yet RecruitingPrimary

Furosemide vs Placebo in Severe Preeclampsia Postpartum

NCT03008616Phase 2TerminatedPrimary

Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

NCT07547046Not Yet RecruitingPrimary

Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia

NCT07220902Phase 3Not Yet RecruitingPrimary

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

NCT07190846Completed

Diastolic Dysfunction 2025

NCT07125599CompletedPrimary

The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia

NCT05283473CompletedPrimary

Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe Preeclampsia

NCT06486025Phase 1Not Yet RecruitingPrimary

Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With Preeclampsia

NCT06385600Not ApplicableNot Yet RecruitingPrimary

Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

NCT06265415Not ApplicableNot Yet RecruitingPrimary

Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine

NCT06219109Unknown

Pulmonary Edema Resolution in Severe Preeclampsia and Eclampsia

NCT04725812Phase 2Terminated

Complement Regulation to Undo Systemic Harm in Preeclampsia

NCT06126068Not ApplicableCompletedPrimary

Comparison of Loading Dose Magnesium Sulphate With Prichard Regimen in the Management of Severe Preeclampsia and Eclampsia.

NCT05310929Not ApplicableCompletedPrimary

Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia

NCT05176652UnknownPrimary

Ultrasonographic Diameter of Optic Nerve Sheath in Fluid Assessment in Severe Preeclamptic Patients

NCT04058405CompletedPrimary

Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia

NCT03661775Not ApplicableCompletedPrimary

Serum Magnesium Level Administration in Severe Pre-eclampsia Obese Pregnancy

Scroll to load more

Research Network

Activity Timeline